Hemophilia A Or B clinical trials

Explore recruiting hemophilia a or b clinical trials.

Recruiting hemophilia a or b studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia A Or B trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

Italy, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

Ireland, Denmark, Italy, France, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX

Belgium, Italy, Romania, Germany, Hungary, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX

France, Poland, Greece, Spain, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hemophilia A Or B trials by city

Hemophilia A Or B in Toronto Hemophilia A Or B in Vancouver Hemophilia A Or B in Montreal Hemophilia A Or B in Calgary Hemophilia A Or B in Edmonton Hemophilia A Or B in Ottawa Hemophilia A Or B in Winnipeg Hemophilia A Or B in Quebec City Hemophilia A Or B in Hamilton Hemophilia A Or B in Kitchener Hemophilia A Or B in London Hemophilia A Or B in Halifax Hemophilia A Or B in New York Hemophilia A Or B in Los Angeles Hemophilia A Or B in Chicago Hemophilia A Or B in Houston

Hemophilia A Or B clinical trials

Recruiting hemophilia a or b studies right now

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Also recruiting in Europe

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX

A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX

Hemophilia A Or B trials by city

Other conditions